drugset / Trial / NCT00006211

A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments

NCT00006211

Phase 2 Completed 350 enrolled Agouron Pharmaceuticals
Treatment

Summary

The purpose of this study is to see if the addition of capravirine to VIRACEPT (nelfinavir mesylate) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) is an effective combination drug therapy for HIV patients who have failed a nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy.

Timeline

Start
2000-02
Primary completion
Completion
2001-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Capravirine Small molecule 1400 mg
Background Nelfinavir Other / unclassified